MARKET WIREad-hoc-news.de • 14h ago
ImageneBio stock heads toward November 11 earnings reportad-hoc-news.de report covering ImageneBio Inc. (IMA) market action, institutional positioning, and fundamental catalysts.
Why IMA Stock advanced +1.24% Today — RQD Quant Desk Flash
$4.10 +1.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.10
ImageneBio Inc. (IMA) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $46.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ImageneBio Inc. (NASDAQ: IMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.10 (+1.24% 1D, market cap $46.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMA ranks #1001 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMA compare to LONA and TIL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMA carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, IMA leads on earnings multiple (N/A) while IMA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMA?
▼
Per IMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835579), ImageneBio Inc. generated $800.0K in revenue (-77.1% YoY), -$45.3M in net income, and -$47.8M in free cash flow against $153.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.10 (+0.03%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMA)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY IMA SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (37% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 38.6 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.25-5.9% Next Q
27
Q2 (-2Q)Grade E$4.00+1.2% Next Q
24
Q3 (-1Q)Grade E$4.05+1.2% Next Q
22
CurrentGrade E$4.10-12% Hist 90D α
19
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMA Turnaround Squeeze
While IMA currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.64) and Max Pain ($4.31) forces dealer call-delta covering toward $9.28.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMA Stock advanced +1.24% Today — RQD Quant Desk Flash
ImageneBio Inc. (IMA) advanced +1.24% to $4.10, trading at 4% of its 52-week range ($3.88 – $8.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($3.88 – $8.84) with RSI-14 at 38.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $4.10 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMA Headlines & Catalysts
CATALYSTwww.dars.gov.et • 17h ago
ImageneBio (IMA) Ends Flat at $4.05 as Traders Balance Support at $3.85 Against Resistance at $4.25 - BPI Reversalwww.dars.gov.et report covering ImageneBio Inc. (IMA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 20h ago
ImageneBio grants 90,775 units: ImageneBio stock sits 55.71 percent below its highad-hoc-news.de report covering ImageneBio Inc. (IMA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 31d ago
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Co
RISK WATCHYahoo Finance • 55d ago
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C
MARKET WIREYahoo Finance • 89d ago
ImageneBio Reports Second Quarter 2026 Financial ResultsSAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highli
MARKET WIREYahoo Finance • 118d ago
ImageneBio Appoints Matt Robbins as General CounselBrings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companiesSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” or
MARKET WIREYahoo Finance • 179d ago
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateSAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program,
MARKET WIREYahoo Finance • 203d ago
ImageneBio Announces $30 Million Private PlacementPrivate placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities for
RISK WATCHYahoo Finance • 159d ago
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkSAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMA)
- ✓Walkthrough of IMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.32%▼ DESCENDING CHANNEL
2026-11-02O $4.20H $4.20L $4.05C $4.10VOL 4.7K
RES: $6.03SUP: $3.52SMA50: $4.64SMA200: $5.62
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMA)
Health Care Rank #1001 of 1016
⚔️ LONA vs IMA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMA vs. LONA, TIL, INMB, CRBU)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ImageneBio Inc. (IMA) ranks #1001 by composite RQD confidence (19/100, grade E) and #762 by equity capitalization ($46.0M). Within this direct 5-issuer industry benchmark cohort, IMA leads on earnings valuation at N/A trailing P/E, while IMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with IMA at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMA
ACTIVE
ImageneBio Inc. | E | 19/100 | — | — | -35.0% | +1.24% | $46.0M | Benchmark Subject |
| LONA LeonaBio Inc. | D- | 36/100 | — | — | -35.0% | +0.61% | $46.3M | /lona-vs-ima → |
| TIL Instil Bio Inc. | D- | 39/100 | — | — | -35.0% | -0.37% | $46.3M | /til-vs-ima → |
| INMB INmune Bio Inc. | E | 31/100 | — | — | -35.0% | -9.37% | $44.4M | /inmb-vs-ima → |
| CRBU Caribou Biosciences Inc. | E | 33/100 | — | — | -35.0% | -4.90% | $47.7M | /crbu-vs-ima → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835579In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImageneBio Inc. (IMA) reported GAAP revenue of $800.0K (-77.1% vs. FY2024 revenue of $3.5M , and -91.3% cumulative change since FY2023) , GAAP net income of -$45.3M, operating cash flow of -$47.8M, and free cash flow of -$47.8M (-124.4% YoY). On the balance sheet, IMA closed FY2025 with $153.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $800.0K | -$45.3M | -$47.8M | -$47.8M | $153.0M | — |
| FY2024 (FY) | 2024-12-31 | $3.5M | -$36.6M | -$21.3M | -$21.3M | $15.9M | — |
| FY2023 (FY) | 2023-12-31 | $9.2M | -$68.2M | -$79.7M | -$79.7M | — | — |
3. IMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ImageneBio Inc. (NASDAQ: IMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.10 (+1.24% 1D, market cap $46.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMA ranks #1001 in composite RQD confidence.
How does IMA compare to LONA and TIL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMA carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, IMA leads on earnings multiple (N/A) while IMA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMA?
Per IMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835579), ImageneBio Inc. generated $800.0K in revenue (-77.1% YoY), -$45.3M in net income, and -$47.8M in free cash flow against $153.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMA trading relative to its 50-day, 200-day, and 52-week technical levels?
IMA last traded at $4.10 (+1.24% on volume of 5,671 shares), positioning the stock -11.64% below its 50-day simple moving average ($4.64) and -27.05% below its 200-day simple moving average ($5.62). Across its 52-week range of $3.88 to $8.84, IMA sits at the 4.4% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($3.62 to $4.58).
IMA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMA stock moving today?
Why IMA Stock advanced +1.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 19/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IMA — ImageneBio Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:47:14Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IMA scores 19 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 1 out of 20, reflecting ROIC of -35% and an FCF yield of 0%. The whale and 13F flow pillar scores 3 out of 20 for institutional accumulation and options positioning. The insider conviction pillar scores 3 out of 20 based on SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 7 out of 20, tied to a beta of 1.0 and sector sensitivity. The forensic balance sheet pillar scores 5 out of 20, reflecting an Altman Z-Score of 0.2, a Piotroski F-Score of 1 out of 9, and a Debt/Equity ratio of 0.5. Taken together, the weakest pillars sit in the cash engine and insider conviction areas. For a prospective investor, the implication is that the rating's upside case rests almost entirely on a turnaround that the current cash generation data does not yet evidence. The valuation tradeoff is that a market capitalization of $46.0M against reported losses leaves little margin for error, and the forensic readings signal elevated distress risk rather than a cheap-entry opportunity.
Recent Catalysts & News Wire Analysis
Per the recent news wire, three items reference IMA. The most recent item, sourced from ad-hoc-news.de, is a headline stating that the stock is heading toward a November 11 earnings report (flagged YELLOW, MARKET WIRE). A second item from www.dars.gov.et reports the stock ending flat at $4.05, with support and resistance levels referenced at $3.85 and $4.25 (flagged GREEN, CATALYST). A third item from ad-hoc-news.de references a grant of 90,775 units and states the stock sits 55.71 percent below its high (flagged YELLOW, MARKET WIRE). The November 11 earnings date is the nearest identified catalyst. Per the Butterfly Supply-Chain Graph, no proprietary signals or butterfly links are present.
Open Questions
- What products or therapies generate the reported revenue, and what drove the decline from $9.2M in FY 2023 to $0.8M in FY 2025?
- What is the source of the increase in reported cash to $94.5M in FY 2025, and is it tied to financing, asset sales, or operations?
- What debt obligations exist, given that debt is reported as N/A across all periods?
- What does the November 11 earnings report need to show to alter the cash engine and forensic pillar readings?
- What is the reported share count and dilution history, given the grant of 90,775 units referenced in the news wire?
IMA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ImageneBio Inc. (IMA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE ad-hoc-news.de • 14h ago
ImageneBio stock heads toward November 11 earnings report ad-hoc-news.de report covering ImageneBio Inc. (IMA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST www.dars.gov.et • 17h ago
ImageneBio (IMA) Ends Flat at $4.05 as Traders Balance Support at $3.85 Against Resistance at $4.25 - BPI Reversal www.dars.gov.et report covering ImageneBio Inc. (IMA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 20h ago
ImageneBio grants 90,775 units: ImageneBio stock sits 55.71 percent below its high ad-hoc-news.de report covering ImageneBio Inc. (IMA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 31d ago
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Co
🔴 RISK WATCH Yahoo Finance • 55d ago
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C
🟡 MARKET WIRE Yahoo Finance • 89d ago
ImageneBio Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highli
🟡 MARKET WIRE Yahoo Finance • 118d ago
ImageneBio Appoints Matt Robbins as General Counsel Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companiesSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” or
🟡 MARKET WIRE Yahoo Finance • 179d ago
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program,
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMA Bull vs. Bear Conversation Board — What's Your Call at $4.10?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $3.56 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IMA (E • RQD 19/100) a Buy at $4.05?
Welcome to the IMA (ImageneBio Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $3.20 (-21.0%)
Spot @ $4.05 Pump the brakes on IMA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IMA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ImageneBio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $5.02 (+24.0%)
Spot @ $4.05 IMA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IMA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.05 (52-wk range $3.88 - $8.84), any beat on forward guidance forces shorts and underweight funds to chase.